恒瑞医药心肌肌球蛋白抑制剂HRS-1893实现海外授权

Core Viewpoint - HengRui Medicine has entered into an exclusive licensing agreement with Braveheart Bio for the development and commercialization of its proprietary Myosin small molecule inhibitor HRS-1893 outside of Greater China [1] Group 1: Agreement Details - HengRui Medicine will receive a total of $75 million, which includes a $65 million upfront payment consisting of $32.5 million in cash and $32.5 million in Braveheart Bio equity, along with a $10 million milestone payment upon completion of technology transfer [1] - The agreement allows Braveheart Bio exclusive rights to develop, manufacture, and commercialize HRS-1893 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1] Group 2: Financial Implications - HengRui Medicine is eligible to receive up to $1.013 billion in milestone payments related to clinical development and sales, in addition to corresponding sales royalties [1]